Mycosis fungoides after treatment with tumor necrosis factor‐alpha inhibitors for psoriasis: progression or onset?

Partarrieu-Mejías, Felipe; Díaz-Corpas, T.; Pérez‐Ferriols, A.; Miquel, V. Alegre-de

doi:10.1111/ijd.14367

Cited by 14 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning patients developing MF after having been treated with systemic therapies, 15 case reports reporting 30 patients have been found (see Table 3). 7,[18][19][20][21][22][23][24][25][26][27][28][29][30][31] Concerning the 27 psoriatic patients receiving biologicals, 18 patients received only 1 biological therapy (etanercept: 6; adalimumab: 5; infliximab: 4; secukinumab: 2; efalizumab: 1) and 9 patients received more than 1 biological therapy (adalimumab: 5; etanercept: 4; infliximab: 2; ustekinumab: 2; apremilast: 2; efalizumab: 1; secukinumab: 1; alefacept: 1; ixekizumab: 1). One additional recent article could not be included in Table 3 due to the lack of specific data.…”

Section: Resultsmentioning

confidence: 99%

“…In the English literature, to our knowledge only 30 case reports have been published reporting the onset of MF in psoriatic patients treated with conventional or biological therapies. 7,[18][19][20][21][22][23][24][25][26][27][28][29][30][31] Three patients received either cyclosporine (two patients) 7,19 or MTX with PUVA (one patient). 18 Twenty-seven cases concerned biological therapies, mostly anti-TNF-alpha, but also anti-IL-23 and anti-IL-17 inhibitors have been described (see Table 3 for details).…”

Section: Discussionmentioning

confidence: 99%

“…18 Twenty-seven cases concerned biological therapies, mostly anti-TNF-alpha, but also anti-IL-23 and anti-IL-17 inhibitors have been described (see Table 3 for details). 7,[18][19][20][21][22][23][24][25][26][27][28][29][30][31] The initial diagnosis of psoriasis had been confirmed by histopathology in 19 cases. After MF diagnosis, the original psoriasis diagnoses were reviewed in 17 cases; in seven patients, the initial diagnosis of psoriasis was confirmed, while in 10 cases, the diagnoses were revised as MF.…”

Section: Discussionmentioning

confidence: 99%

“…Psoriasis has been associated with different comorbidities 12 and risk of malignancies 13 including non-Hodgkin lymphoma (NHL) and cutaneous T-cell lymphoma (CTCL). [14][15][16][17] Specifically, in recent years patients who developed MF after systemic treatment for psoriasis 7,[18][19][20][21][22][23][24][25][26][27][28][29][30][31] have been reported, and some authors suggested that the association between MF and psoriasis is not infrequent. 32,33 We performed an extensive literature review in order to examine the risk of developing MF in psoriatic patients, particularly those under biological treatments.…”

Section: Introductionmentioning

confidence: 99%

“…Psoriasis has been associated with different comorbidities and risk of malignancies including non‐Hodgkin lymphoma (NHL) and cutaneous T‐cell lymphoma (CTCL) . Specifically, in recent years patients who developed MF after systemic treatment for psoriasis have been reported, and some authors suggested that the association between MF and psoriasis is not infrequent …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Risk of mycosis fungoides in psoriatic patients: a critical review

Biondo

Cerroni

Brunasso

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Psoriasis has been controversially associated with risk of non-Hodgkin lymphoma (NHL) and mycosis fungoides (MF). Also patients who developed MF after systemic treatment for psoriasis have been reported, and some authors suggested that the association between MF and psoriasis is not infrequent. We performed an extensive literature review in order to examine the risk of developing MF in psoriatic patients with a systematic search of the English-language databases. An increased risk for lymphoma overall in psoriatic patients has been found only by three out of seven studies. The risk of developing MF in psoriatic patients has been investigated by different studies in different populations and with different methodologies presenting bias and limitations, and it seems reasonable that misclassification between psoriasis and MF may explain the association reported. In contrast to the large number of psoriatic patients treated with biologicals, only 27 case reports of MF after biological therapy for psoriasis have been reported, and in 10 cases, the initial psoriasis diagnoses were then revised as MF. A true association between MF and psoriasis is possible, but the real incidence and prevalence are still unknown. The reported higher risk of developing MF in psoriatic patients should be reconsidered in the light of the bias of misclassification and the low magnitude reported in previous studies. There is not enough evidence to support a causal relation among biological therapies and MF in psoriatic patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Risk of mycosis fungoides in psoriatic patients: a critical review

Biondo

Cerroni

Brunasso

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies

Davis,

Spencer,

Johnson

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Background The risk of developing cutaneous T cell lymphoma (CTCL) in patients using psoriasis biologics has not been well characterized. The goals of this review were to investigate the incidence of CTCL in patients with psoriasis receiving biologic therapy in clinical trials and psoriasis registries, and to review cases of CTCL and biologic use reported in scientific publications. Methods The US National Library of Medicine clinical trials database (clinicaltrials.gov) was queried to identify phase 3 and 4 clinical trials of the 12 biologic agents currently FDA approved for psoriatic disease. The incidence of CTCL in these trials was examined and summarized. To examine the incidence of CTCL in psoriasis registries, a Medline search was conducted. Finally, we performed a systematic review of CTCL cases reported in the literature. Results Only two cases of CTCL were reported in 35,801 subjects with psoriasis receiving a biologic agent in the active arm of 108 psoriasis phase 3 clinical trials. One of these CTCL cases was determined by the investigator to be CTCL misdiagnosed as psoriasis prior to randomization. No cases of CTCL were reported in 5440 subjects with psoriasis in 34 phase 4 clinical trials. Only one case of CTCL was identified in 34,111 registry subjects. In the literature, tumor necrosis factor (TNF) inhibitors had the highest number of reported cases of CTCL (34 cases), followed by interleukin (IL)-17 inhibitors (7 cases), and IL-12/23 inhibitors (6 cases). No cases of CTCL were found to be reported with IL-23 inhibitors. Conclusion Our findings indicate that the development of CTCL is rare in the setting of psoriasis biologic use. Of the limited number of cases of CTCL found, most were in the setting of TNF inhibitor use and no cases of CTCL were reported in the setting of IL-23 inhibitor use. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-023-01074-z.

show abstract